ad

Invicta Diagnostic IPO Subscription Day 2

Posted by : sachet | Tue Dec 02 2025

Invicta Diagnostic IPO Subscription Day 2

Here, the Invicta Diagnostic IPO launched on 1st December 2025. The bidding for the issue will close on 3rd December 2025. The primary aim of the Invicta Diagnostic IPO is to raise ₹28.12 crores from the market. Also, the Invicta Diagnostic IPO has received an impressive level of subscription, indicating that the shares will be listed at an impeccable premium. Scroll down to check the Invicta Diagnostic IPO subscription and details. 

Invicta Diagnostic IPO Details 

IPO Open Date1st December 2025
Face Value ₹10 per share
Price Band₹80 and ₹85 per share
Lot Size1,600 shares
Issue TypeBookbuilding IPO
Listing AtNSE & SME
IPO Close Date 3rd December2025
Listing Date 8th December 2025

The price band for Invicta Diagnostic’s IPO has been set at Rs 80 to Rs 85, and a total of 33,08,800 shares are being issued. Let’s segregate the share quota fixed for different categories of investors. 

CategoriesShares Offered% of shares Offered
Market Maker Shares Offered1,66,4005.03%
Qualified Institutional Investors13,32,80040.28%
Non-Institutional Investors5,42,40016.39%
Retail Investors12,67,20038.30%
Total Shares Offered33,08,800100.00%

Invicta Diagnostic IPO Subscription Status

As of now, the Invicta Diagnostic IPO has been subscribed to 0.95 times. Of these, 0.78  times are subscribed by retail investors, 0.74 times by non-institutional investors, and 1.55 times by QII (Qualified Institutional Investors).  

The healthy subscription status indicates that investors are expecting higher returns at the time of the Invicta Diagnostic IPO listing on 8th December 2025. Invicta Diagnostic also has a positive outlook on the fresh issue of 33,00,000 shares, which is expected to raise around Rs 28.12 crores.

Invicta Diagnostic IPO GMP Today

Invicta Diagnostic IPO GMP

We know that higher subscription levels drive grey-market premiums for IPOs. Let’s explore the Invicta Diagnostic IPO GMP for 1st December 2025. 

The grey market premium for this IPO has surged to 0.00% or Rs 0 per share. It indicates that the estimated listing price per share is Rs 85. Numerous factors played a pivotal role in this jump in Invicta Diagnostic’s IPO GMP. These include higher subscription rates, favourable market sentiment, and investors’ positive attitude towards IPOs. 

GMP DateIPO PriceGMPEstimated Listing Price Estimated Listing Gains
2-12-2025₹85.00₹0.00₹85.000.00%
1-12-2025₹85.00₹0.00₹85.000.00%
30-11-2025₹85.00₹0.00₹85.000.00%
29-11-2025₹85.00₹0.00₹85.000.00%
28-11-2025₹85.00₹0.00₹85.000.00%
27-11-2025₹85.00₹0.00₹85.000.00%
26-11-2025₹85.00₹0.00₹85.000.00%

About Invicta Diagnostic Ltd.

Invicta Diagnostics was established in January 2021. Invicta Diagnostic Limited offers radiology and pathology solutions. The company provides pathology and radiology testing, including imaging, radiology, and teleradiology, under the brand ‘PC Diagnostics’ through 7 diagnostic centres and a central laboratory across Mumbai, Maharashtra. Invicta Diagnostics Limited (trading as PC Diagnostics) is a Mumbai-based diagnostic services company specialising in integrated pathology and radiology solutions. The company follows a hub‑and‑spoke model across the Mumbai Metropolitan Region, featuring:

  1. Flagship Hub
  2. Three additional hubs are Bhayandar, Byculla, and Marol
  3. Three spokes in Lower Parel, Sewri and Kalwa

The company offers around 60 routine and 487 specialised pathology tests, plus about 96 basic and 130 advanced radiology tests.

Invicta Diagnostic Limited Financials

The company’s financial analysis is essential before applying for the Invicta Diagnostic IPO. Look at the table to learn about Invicta Diagnostic  Limited’s financials. 

Year Ended30th September 2025 (in cr.)31st March 2025 (in cr.)31st March 2024 (in cr.)
Assets34.9021.2215.89
Revenue17.0830.1815.90
Profit After Tax4.084.933.81
EBITDA6.779.207.09
Net Worth23.6813.608.67
Reserves and Surplus14.425.188.54
Total Borrowing3.723.543.81

Explanation

Invicta Diagnostic  Limited’s revenue soared by 90% from ₹15.90 crores in March 2024  to ₹30.18 crores in March 2025. Moreover, the company’s PAT increased by 30% from ₹3.81 crores in March 2024 to ₹4.93 crores in March 2025.

Technical Analysis

Several technical indicators are available to assess a company’s potential to deliver returns. Use the parameters mentioned below to analyse the technicals of the Invicta Diagnostic IPO.

Key IndicatorsValue
PE Ratio (Price-to-Earnings) 15.97
EPS (Earnings Per Share)5.32
RoNW36.25%
ROCE42.00%
ROE44.28%
EBITDA Margin30.57%
Price to Book Value5.26
Market Capitalisation₹106.86 Cr.

Invicta Diagnostic IPO Listing Expectations

Invicta Diagnostic Highlights: IPO allotment is still pending, as the bid will close today. However, given the current GMP or market sentiment, it is reasonable to expect higher listing gains for the share. A 0.00% jump in Yash Highlight GMP suggests the estimated listing price per share will be around Rs 85.

It will provide higher listing gains to investors who applied for this IPO. Also, the financial fundamentals of this business made it the experts’ top long-term recommendation. 

Invicta Diagnostic IPO Dates

IPO Open Date1st December 2025
IPO Close Date3rd December 2025
Allotment4th December 2025
Refund Date5th December 2025
IPO Listing Date8th December 2025

Note: IPO GMP is volatile and depends on market sentiment. Hence, one should conduct their research before investing in it.

Recent Articles

Icodex Publishing Solutions IPO GMP: Day 1 IPO Live Updates

Bluestone Jewellery IPO GMP: Day 1 IPO Live Updates

Highway Infrastructure IPO Listing Preview: What to Expect Now in 2025?

Concord Biotech Q1 Results FY26: Q1 PAT Falls 26.07% to ₹44.06 Crore; Revenue Down 5.47% YoY

Action Construction Equipment Q1 Results FY26: Q1 PAT Rises 16.08% to ₹97.72 Crore; Revenue Down 11.19% YoY

Sawaliya Foods Products IPO Allotment Status Check Online: GMP, Subscription, Price, and More

Invicta Diagnostic IPO Allotment Status Check Online: GMP, Subscription, Price, and More

Mahendra Realtors IPO GMP & Review: Apply or Avoid?

Regaal Resources IPO GMP & Review: Apply or Avoid?

Icodex Publishing Solutions IPO GMP & Review: Apply or Avoid?